Charles A. Thornton, M.D. University of Rochester
Principal Investigatorwork Box 673 601 Elmwood Ave Rochester NY 14642 office: MC 5-5207 p (585) 275-2542 firstname.lastname@example.org Research Focus: Neurogenetic disorders, including myotonic dystrophy; therapeutics, including antisense approaches.
Graduate Studentwork Rochester NY email@example.com Research Focus: Molecular biology/neuroscience
Graduate Studentwork Rochester NY firstname.lastname@example.org Research Focus: Expanded repeat DNA tracts and their roles in splicing-mediated disease in myotonic dystrophy
Graduate Studentwork Rochester NY email@example.com Research Focus: Understanding the pathogenesis of myotonic dystrophy and developing new therapies
- Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.PLoS Genet. 12, e1006316. (2016 Sep 01).
- Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.Hum Mol Genet, . (2016 Aug 13).
- Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.J Pharmacol Exp Ther. 355, 329-40. (2015 Nov 01).